Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. Academic Article uri icon

Overview

abstract

  • In AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses. A stepwise logistic regression procedure selected polymorphisms associated with reduced drug clearance adjusted for body mass index and the composite CYP2B6 516/983 genotype. Relationships between selected polymorphisms and treatment responses were characterized by competing risk methodology. Association analyses involved 821 individuals (317 for pharmacokinetics and 643 for treatment response). Models that included CYP2B6 516/983 genotype best predicted pharmacokinetics. Slow-metabolizer genotypes were associated with increased central nervous system events among white participants and decreased virologic failure among black participants.

publication date

  • September 1, 2010

Research

keywords

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Anti-HIV Agents
  • Aryl Hydrocarbon Hydroxylases
  • Benzoxazines
  • Cytochrome P-450 CYP3A
  • Oxidoreductases, N-Demethylating
  • Polymorphism, Single Nucleotide
  • Reverse Transcriptase Inhibitors

Identity

PubMed Central ID

  • PMC2919241

Scopus Document Identifier

  • 77955685573

Digital Object Identifier (DOI)

  • 10.1086/655470

PubMed ID

  • 20662624

Additional Document Info

volume

  • 202

issue

  • 5